Last updated: March 18, 2024
Sponsor: Hospital Beatriz Ângelo
Overall Status: Active - Recruiting
Phase
N/A
Condition
Gastric Cancer
Pancreatic Disorders
Pancreatic Cancer
Treatment
Standard Care
Combined Exercise and Dietary Intervention (CEDI)
Clinical Study ID
NCT05420259
213/18
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- gastric or pancreatic cancer stage II/III, eligible for neoadjuvant chemotherapy,
- age higher than 40 years and lower than 80 years,
- ECOG (Eastern Cooperative Oncology Group) functional status: 0-2,
- sedentary/low physical activity level.
Exclusion
Exclusion Criteria:
- life expectancy less than 12 months at inclusion,
- chemotherapy regimen other than 5-Fluorouracil, Folinic acid, Oxaliplatin, Docetaxel (FLOT) for gastric and 5-Fluorouracil, Irinotecan and Oxaliplatin (FOLFIRINOX) orgemcitabine for pancreatic cancer,
- metastatic disease,
- chronic anti-inflammatory medication use,
- known inflammatory condition (rheumatoid arthritis, ankylosing spondylitis or chronicactive hepatitis)
- cardiovascular, respiratory or musculoskeletal or joint problems that precludemoderate physical activity.
Study Design
Total Participants: 68
Treatment Group(s): 2
Primary Treatment: Standard Care
Phase:
Study Start date:
March 21, 2022
Estimated Completion Date:
June 28, 2024
Connect with a study center
Hospital Beatriz Ângelo
Loures, Lisboa 2674-514
PortugalActive - Recruiting
Hospital da Luz
Lisboa,
PortugalSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.